LeMaitre warning letter looks manageable, says Roth Capital

Roth Capital believes the FDA warning letter sent to LeMaitre (LMAT) “looks quite manageable.” The letter addressed six 483 observations regarding flaws in the company’s quality system at its North Brunswick, New Jersey location which produces the Artegraft biologic graft, the analyst tells investors in a research note. Roth believes the observations are addressable and not represent a systemic issue. It believes LeMaitre’s Artegraft sales will not be impacted and keeps a Buy rating on the shares with a $106 price target